Search Results for 'Asco-Melanoma'

Asco-Melanoma published presentations and documents on DocSlides.

GIULIANA  D’AURIA UOC Oncologia ASL Roma 2
GIULIANA D’AURIA UOC Oncologia ASL Roma 2
by hadley
Osp. . Pertini-S.Eugenio-CTO. Therapeutic. . app...
Meeting summary ASCO GU 2020,
Meeting summary ASCO GU 2020,
by patricia
San Francisco. , USA. Assoc. . Prof. . Shilpa Gupt...
CONKO-007: Chemoradiotherapy vs
CONKO-007: Chemoradiotherapy vs
by davies
Chemotherapy Alone for Unresectable . Locally Adva...
 Randomized Comparison of Adjuvant Aromatase Inhibitor <br />Exemestane plus Ovarian Function
Randomized Comparison of Adjuvant Aromatase Inhibitor <br />Exemestane plus Ovarian Function
by tatiana-dople
Presented By Olivia Pagani at 2014 ASCO Annual Me...
HER2 TESTING IN BREAST CANCER
HER2 TESTING IN BREAST CANCER
by danika-pritchard
Clinical Practice Guideline Update. American Soci...
Genetic plasma cell signatures in high-risk smoldering myel
Genetic plasma cell signatures in high-risk smoldering myel
by trish-goza
Presented By Sham Mailankody at 2016 ASCO Annual ...
DISCOVER THE AWESOME POWER OF THE ASCO LOW VOLTAGE  7000 SERIES GENERA
DISCOVER THE AWESOME POWER OF THE ASCO LOW VOLTAGE 7000 SERIES GENERA
by conchita-marotz
The ASCO 7000 ERIES Generator Paralleling Control...
ASCO 2010:
ASCO 2010:
by phoebe-click
. Highlights from the Annual Clinical Meeting. G...
HER2 TESTING IN BREAST CANCER
HER2 TESTING IN BREAST CANCER
by danika-pritchard
Clinical Practice Guideline Update. American Soci...
Meeting summary asco  2020, virtual meeting
Meeting summary asco 2020, virtual meeting
by neo548
Brittni. . Prosdocimo. , . MSN, RN, . BMTCN. . U...
Targeting EGFR Exon 20 insertions
Targeting EGFR Exon 20 insertions
by unita
Gregory J. Riely. November 2021. What about those ...
Broadening Eligibility Criteria to Make Clinical Trials More Representative
Broadening Eligibility Criteria to Make Clinical Trials More Representative
by elena
Joint Recommendations of the American Society of C...
nmCRPC  ASCO GU 2018 Bobby Shayegan, MD FRCSC
nmCRPC ASCO GU 2018 Bobby Shayegan, MD FRCSC
by kylie
Associate Professor & Head. David . Braley. &...
NASPCC: Chemotherapy Options for Advanced Prostate Cancer
NASPCC: Chemotherapy Options for Advanced Prostate Cancer
by ceila
Jeanny B. Aragon-Ching, M.D., F.A.C.P.. Clinical P...
Oncological  Surgyery : 1. ASCO:
Oncological Surgyery : 1. ASCO:
by queenie
Lyman. GH, . Bohlke. K, . Khorana. AA, et al. ....
Year in Review Prostate Cancer
Year in Review Prostate Cancer
by faith
Emmanuel . S . Antonarakis. , MD. Professor of Onc...
TRK fusion-positive cancer highlights from ASCO 2022
TRK fusion-positive cancer highlights from ASCO 2022
by joanne
Prof. David S. Hong. Medical Oncologist. MD Anders...
Updates in the systemic treatment for lung
Updates in the systemic treatment for lung
by madeline
cancer: Immunotherapy. Oscar Arrieta MD. Thoracic....
Checkpoint inhibitors  for
Checkpoint inhibitors for
by paisley
NSCLC. An update. Solange Peters, MD-PhD. Oncology...
Denise A. Yardley, MD Sarah Cannon Research Institute
Denise A. Yardley, MD Sarah Cannon Research Institute
by lily
Senior Investigator, . Breast Cancer Research. Ten...
mCODE Community of Practice Monthly Meeting
mCODE Community of Practice Monthly Meeting
by jocelyn
Chairs – Rob Dingwell & Zeshan Rajput. Suppo...
Jchem  applications in  Medchem
Jchem applications in Medchem
by StarsAndStripes
Prediction. . and. . Data Sorting. Zhengtao. Li...
Presented at the American Society of Clinical Oncology ASCO Annual Mee
Presented at the American Society of Clinical Oncology ASCO Annual Mee
by eliza
8 2021Patientswithhigh-doselymphodepletionCohort2w...
ASCO 2012 Review Gynecologic Cancer
ASCO 2012 Review Gynecologic Cancer
by welnews
Nelson Teng, M.D., Ph.D.. Director, Gynecologic On...
Behandeling van het recidief ovariumcarcinoom
Behandeling van het recidief ovariumcarcinoom
by sandsomber
Ignace Vergote MD PhD FACS FSPS. Chairman, Leuven ...
Best of ASCO GU Session Sandy Srinivas.MD
Best of ASCO GU Session Sandy Srinivas.MD
by experimentgoogle
Stanford University. Outline. Abstract #4. :. . I...
 Ovarian cancer with update from ASCO 2013
Ovarian cancer with update from ASCO 2013
by karlyn-bohler
Siew. . wei. . wong. Oncology registrar. Epidem...
ASCO 2019 NSCLC - PARP & Chemotherapy
ASCO 2019 NSCLC - PARP & Chemotherapy
by mitsue-stanley
ASCO 2019 NSCLC - PARP & Chemotherapy REF Stu...
Ezra  W Cohen University of California, San Diego
Ezra W Cohen University of California, San Diego
by natalia-silvester
Ezra W Cohen University of California, San Diego...
Updates in the Treatment of Breast cancer
Updates in the Treatment of Breast cancer
by alexa-scheidler
Mohammad . Jahanzeb. , MD, FACP. Professor of Cli...
Updates on the Use of Adjuvant Therapy in HER2-Positive Breast Cancer
Updates on the Use of Adjuvant Therapy in HER2-Positive Breast Cancer
by danika-pritchard
ASCO-CAP Recommendations For HER2 Testing in Brea...
Primer on Kinase Inhibitors
Primer on Kinase Inhibitors
by giovanna-bartolotta
Richard R. Furman. Directory, CLL Research Center...
Going to the Gulf  Our Experience in Qatar
Going to the Gulf Our Experience in Qatar
by alexa-scheidler
Sam Murdock – Director of Water Services. Enter...
James Yang,
James Yang,
by pasty-toler
MD. The Evolving Treatment Landscape in NSCLC: Co...
The CREST Trial
The CREST Trial
by kittie-lecroy
Presented By James Hill at 2016 ASCO Annual Meeti...
Using Non-targeted Therapies in Targeted Lung Cancer Popula
Using Non-targeted Therapies in Targeted Lung Cancer Popula
by ellena-manuel
Nathan Pennell, M.D., Ph.D.. September 6, 2014. O...
Membership Application Every Oncology Professional Everywhere Should be an ASCO Member
Membership Application Every Oncology Professional Everywhere Should be an ASCO Member
by min-jolicoeur
EXPERIENCE THE VALUE OF ASCOS GLOBAL COMMUNITY Th...
Understanding Bubbly Episodes By ASCO M
Understanding Bubbly Episodes By ASCO M
by alexa-scheidler
C ARVALHO A LBERTO ARTIN AND AUME ENTURA Wealth ...